logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

On September 16, 1986, TSAKER NE spent 19,800 Hong Kong dollars to repurchase 25,000 shares.

date
16/09/2025
avatar
GMT Eight
EcoGreen Energy (01986) announced that the company spent HKD 19,800,000 to buy back...
Tsaker NE (01986) announced that the company will buy back 25,000 shares at a price of 0.79 Hong Kong dollars per share on September 16, 2025, with a total investment of 19,800 Hong Kong dollars.
Related Articles
HK Stock
Health 160 (02656): Hong Kong public offering received 751.77 times oversubcribed, listing on September 17th.
HK Stock
JOIN-SHARE (01543) has entered into a business cooperation agreement with Zhongshan Financial Investment.
HK Stock
Jiangsu Hengrui Pharmaceuticals (01276): Injection SHR-1826, Adelbeli monoclonal antibody injection, Bevacizumab monoclonal antibody injection obtained drug clinical trial approval letter.
Health 160 (02656): Hong Kong public offering received 751.77 times oversubcribed, listing on September 17th.
HK Stock
JOIN-SHARE (01543) has entered into a business cooperation agreement with Zhongshan Financial Investment.
HK Stock
Jiangsu Hengrui Pharmaceuticals (01276): Injection SHR-1826, Adelbeli monoclonal antibody injection, Bevacizumab monoclonal antibody injection obtained drug clinical trial approval letter.
HK Stock
RECOMMEND
SAFE Enhances Convenience of Cross-Border Investment and Financing
SAFE Enhances Convenience of Cross-Border Investment and Financing
icon
16/09/2025
U.S. Moves to Expand Strategic Uranium Reserves as Nuclear Sector Stocks Rally
U.S. Moves to Expand Strategic Uranium Reserves as Nuclear Sector Stocks Rally
icon
16/09/2025
From Falling Orders to Surging Fertilizer Costs, U.S. Farmers Confront a “Trade and Fiscal Cliff”
From Falling Orders to Surging Fertilizer Costs, U.S. Farmers Confront a “Trade and Fiscal Cliff”
icon
16/09/2025
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.